The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma.
Please note that following on from advice received from the company this appraisal has been rescheduled into the work programme
For information, we anticipate that the appraisal will begin during mid-November 2020 when we will write to you about how you can get involved.